Drug Guide
Perphenazine
Classification
Therapeutic: Antipsychotic
Pharmacological: Phenothiazine (Typical antipsychotic)
FDA Approved Indications
- Schizophrenia
- Nausea and vomiting (off-label)
Mechanism of Action
Perphenazine blocks dopamine D2 receptors in the brain, thereby reducing symptoms of psychosis and controlling nausea.
Dosage and Administration
Adult: Initially 4-8 mg three times daily. Dosage can be adjusted based on response and tolerability.
Pediatric: Use not generally recommended; consult a specialist.
Geriatric: Start with lower doses, such as 2-4 mg two to three times daily, due to increased sensitivity.
Renal Impairment: Adjust doses carefully; no specific guidelines well established.
Hepatic Impairment: Use cautiously; no specific dose adjustments established.
Pharmacokinetics
Absorption: Well absorbed from gastrointestinal tract.
Distribution: Widely distributed, crosses blood-brain barrier.
Metabolism: Hepatic via CYP450 enzymes.
Excretion: Primarily via urine, some in feces.
Half Life: 6-12 hours, variable.
Contraindications
- Comprise hypersensitivity to phenothiazines or other components.
- Comorbid Parkinson's disease.
- Bone marrow suppression.
Precautions
- Use cautiously in elderly, due to risk of sedation, orthostatic hypotension, and increased mortality in elderly with dementia-related psychosis.
- Monitor for extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, and other adverse effects.
Adverse Reactions - Common
- Drowsiness (Common)
- Extrapyramidal symptoms (EPS) (Common)
- Dry mouth (Common)
- Blurred vision (Common)
Adverse Reactions - Serious
- Neuroleptic malignant syndrome (NMS) (Rare)
- Tardive dyskinesia (Rare)
- Seizures (Rare)
- Blood dyscrasias (e.g., agranulocytosis) (Rare)
Drug-Drug Interactions
- Centrally acting depressants (additive sedation)
- Anticholinergic medications (increased anticholinergic effects)
Drug-Food Interactions
- Alcohol (enhanced sedation)
Drug-Herb Interactions
N/ANursing Implications
Assessment: Monitor mental status, extrapyramidal symptoms, blood pressure, and signs of NMS.
Diagnoses:
- Risk for falls (due to sedation and orthostatic hypotension)
- Risk for neurological injury related to EPS or NMS
Implementation: Administer with food to decrease gastrointestinal upset; monitor for adverse reactions.
Evaluation: Assess effectiveness in controlling psychotic symptoms and side effects regularly.
Patient/Family Teaching
- Take medication exactly as prescribed.
- Do not stop medication abruptly.
- Report any signs of EPS, NMS, or unusual movements.
- Avoid alcohol and operating heavy machinery until response is known.
Special Considerations
Black Box Warnings:
- Increased mortality in elderly patients with dementia-related psychosis.
- Tardive dyskinesia may be irreversible.
Genetic Factors: Metabolism variability may influence drug levels; CYP450 enzyme activity may affect response.
Lab Test Interference: May cause false-positive results in certain laboratory tests.
Overdose Management
Signs/Symptoms: Extrapyramidal symptoms, hypotension, sedation, seizures, respiratory depression, coma.
Treatment: Supportive care, monitor vital signs, activated charcoal if early, symptomatic treatment for seizures or other adverse effects.
Storage and Handling
Storage: Store at room temperature, away from light and moisture.
Stability: Stable for usual shelf life, check packaging for expiration date.